Concurrent Radiotherapy and Taxane Chemotherapy in Patients with Locoregional Recurrence of Breast Cancer

Semrau, Sabine; Gerber, Bernd; Reimer, Toralf; Klautke, Günther; Fietkau, Rainer

doi:10.1007/s00066-006-1549-1

Cited by 19 publications

(12 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Presumably, a tumoricidal effect of the irradiation must be achieved before recalcification. This is supported by the fact that concurrent chemotherapy reinforces this effect [23] in analogy to solid tumors [11,30,31]. Moreover, recalcification was detected only at total doses of > 20 Gy.…”

Section: Recalcificationsupporting

confidence: 56%

Total and Single Doses Influence the Effectiveness of Radiotherapy in Palliative Treatment of Plasmacytoma

et al. 2008

Self Cite

View full text Add to dashboard Cite

Radiotherapy is a very effective palliative treatment. Patients with a reduced general condition, with multiple bone lesions and a poor prognosis profit from short-term schemes (e.g., 1 x 8 Gy to 10 x 3 Gy). Patients in good general condition with a life expectancy of > 1 year and an osteolysis at risk of fracture, should be treated with doses up to 40-50 Gy (20-25 x 2 Gy), in order to achieve the best possible recalcification and pain relief.

show abstract

Section: Recalcificationsupporting

confidence: 56%

Total and Single Doses Influence the Effectiveness of Radiotherapy in Palliative Treatment of Plasmacytoma

et al. 2008

Self Cite

View full text Add to dashboard Cite

show abstract

“…For a number of years now preoperative (neoadjuvant), rather than postoperative, radiotherapy has been shown to be effective at reducing local relapses in a variety of cancer types [1-6]. In locally advanced rectal cancer, the addition of 5-fluorouracil (5-FU) to preoperative radiotherapy has been shown to improve pathological complete response rate, tumour downstaging [7] and locoregional control [8,9] compared with radiotherapy alone.…”

Section: Introductionmentioning

confidence: 99%

Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer

2010

View full text Add to dashboard Cite

BackgroundThis study evaluated the effectiveness and safety of preoperative chemoradiotherapy with capecitabine in patients with locally advanced resectable rectal cancer. This report summarizes the results of the phase II study together with long-term (5-year) follow-up.MethodsBetween June 2004 and January 2005, 57 patients with operable, clinical stage II-III adenocarcinoma of the rectum entered the study. Radiation dose was 45 Gy delivered as 25 fractions of 1.8 Gy. Concurrent chemotherapy with oral capecitabine 825 mg/m2 twice daily was administered during radiotherapy and at weekends. Surgery was scheduled 6 weeks after the completion of the chemoradiotherapy. Patients received four cycles of postoperative chemotherapy comprising either capecitabine 1250 mg/m2 bid days 1-14 every 3 weeks or bolus i.v. 5-fluorouracil 425 mg/m2/day and leucovorin 20 mg/m2/day days 1-5 every 4 weeks (choice was at the oncologist's discretion). Study endpoints included complete pathological remission, proportion of R0 resections and sphincter-sparing procedures, toxicity, survival parameters and long-term (5-year) rectal and urogenital morbidity assessment.ResultsOne patient died after receiving 27 Gy because of a pulmonary embolism. Fifty-six patients completed radiochemotherapy and had surgery. Median follow-up time was 62 months. No patients were lost to follow-up. R0 resection was achieved in 55 patients. A complete pathological response was observed in 5 patients (9.1%); T-, N- and overall downstaging rates were 40%, 52.9% and 49.1%, respectively. The 5-year overall survival rate, recurrence-free survival, and local control was 61.4% (95% CI: 48.9-73.9%), 52.4% (95% CI: 39.3-65.5%), and 87.4% (95% CI: 75.0-99.8%), respectively. In 5 patients local relapse has occurred; dissemination was observed in 19 patients and secondary malignancies have occurred in 2 patients. The most frequent side-effect of the preoperative combined therapy was dermatitis (grade 3 in 19 patients). The proportion of patients with severe late (SOMA grade 3 and 4) rectal, bladder and sexual toxicity was 40%, 19.2% and 51.7%, respectively.ConclusionsThis study confirms data from other non-randomised studies that capecitabine-based preoperative chemoradiation is a feasible treatment option for locally advanced rectal cancer, with positive 5-year overall survival, recurrence-free survival, and local control rates.

show abstract

“…Simultaneous radiochemotherapy is increasingly used in a variety of cancer types for mainly improving local control [12,21,25,31]. In locally advanced rectal cancer, preoperative radiochemotherapy with 5-fluorouracil (5-FU) improves local control and reduces the risks of acute and late toxicity as compared to postoperative radiochemotherapy [28].…”

Section: Introductionmentioning

confidence: 99%

Neoadjuvant Capecitabine Combined with Standard Radiotherapy in Patients with Locally Advanced Rectal Cancer

et al. 2008

View full text Add to dashboard Cite

show abstract

Concurrent Radiotherapy and Taxane Chemotherapy in Patients with Locoregional Recurrence of Breast Cancer

Abstract: Concurrent irradiation and taxane chemotherapy weekly, in particular with paclitaxel, is recommended due to response and acceptable side effects for treatment of inoperable locoregional breast cancer recurrence.

Cited by 19 publications

References 29 publications

Total and Single Doses Influence the Effectiveness of Radiotherapy in Palliative Treatment of Plasmacytoma

Total and Single Doses Influence the Effectiveness of Radiotherapy in Palliative Treatment of Plasmacytoma

Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer

Neoadjuvant Capecitabine Combined with Standard Radiotherapy in Patients with Locally Advanced Rectal Cancer

Contact Info

Product

Resources

About